Research Articles

Acute rejection occurs when the recipient's immune system recognizes donor alloantigens as foreign. In T-cell mediated rejection (TCMR), recipient antigen-presenting cells (APCs) process donor HLA peptides and present them to naive T cells via the indirect pathway, while donor APCs directly stimulate recipient T cells via the direct pathway. A third "semi-direct" pathway involves transfer of intact donor HLA molecules to recipient APCs.

Activated CD4+ helper T cells drive the rejection response by producing inflammatory cytokines (IFN-gamma, IL-2, TNF) that recruit and activate macrophages and CD8+ cytotoxic T lymphocytes. CTLs directly kill graft cells through perforin/granzyme and Fas/FasL pathways. The Banff classification grades TCMR based on interstitial inflammation, tubulitis, and intimal arteritis severity.

Antibody-mediated rejection (AMR) involves de novo or preformed donor-specific antibodies (DSA) binding to HLA class I/II molecules on graft endothelium. This triggers complement activation (C4d deposition), Fc receptor-mediated NK cell cytotoxicity (ADCC), and direct endothelial activation. The 2019 Banff update refined AMR diagnostic criteria to include molecular markers (gene expression classifiers) alongside traditional histology and DSA detection.

The standard triple immunosuppression regimen (calcineurin inhibitor + antimetabolite + corticosteroid) has been the backbone of transplant medicine for decades, with tacrolimus/mycophenolate mofetil/prednisone as the most common combination. While highly effective at preventing acute rejection, long-term CNI nephrotoxicity and metabolic complications remain significant limitations.

Belatacept, a CTLA-4 Ig fusion protein that blocks T cell costimulation, offers a CNI-free maintenance strategy. The BENEFIT study showed superior kidney function at 7 years compared to cyclosporine-based regimens, though early rejection rates were higher. Updated protocols combining belatacept with intensified induction (thymoglobulin) and early MMF optimization have improved outcomes.

Novel approaches targeting the B cell/antibody axis are addressing chronic AMR, the leading cause of late graft loss. Clazakizumab (anti-IL-6), felzartamab (anti-CD38), and BAFF/APRIL inhibitors are in clinical trials for DSA reduction and chronic AMR treatment. Complement inhibitors (eculizumab, C1-INH) have shown benefit in highly sensitized patients. Tolerogenic strategies, including regulatory T cell infusion and mixed chimerism protocols, represent the ultimate goal of operational tolerance without chronic immunosuppression.

Donor-derived cell-free DNA (dd-cfDNA) has emerged as the leading non-invasive biomarker for rejection detection. Released from injured graft cells into the recipient's bloodstream, dd-cfDNA levels above 1% in kidney transplants and 0.25% in heart transplants correlate strongly with active rejection. FDA-cleared assays (AlloSure, Prospera) are now integrated into clinical practice, with serial monitoring reducing biopsy rates by 30-50%.

Urinary chemokines, particularly CXCL9 and CXCL10, provide organ-specific (kidney) biomarkers reflecting intrarenal inflammation. These interferon-gamma-induced chemokines are produced by tubular epithelial cells during TCMR and correlate with histological rejection severity. Combined dd-cfDNA and urinary CXCL9 panels achieve sensitivity >90% and specificity >80% for detecting clinically significant rejection.

The Molecular Microscope Diagnostic System (MMDx) uses microarray gene expression profiling of biopsy tissue to provide objective, automated Banff scores and molecular diagnoses. Machine learning algorithms trained on thousands of biopsies can classify rejection subtypes, predict progression, and identify treatment-resistant phenotypes that conventional histology misses. As sequencing costs decrease, gene expression panels applied to peripheral blood (e.g., TruGraf) may eventually replace tissue-based molecular diagnostics.